EICHORCondition: Atopic Dermatitis · Atopic · Dermatitis · Sponsor: Apollo Therapeutics Ltd
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Medical Dermatology Specialists, PC/US Dermatology Partners | Phoenix, Arizona, United States | — |
| California Dermatology & Clinical Research Institute | Encinitas, California, United States | — |
| First OC Dermatology Research, Inc. | Fountain Valley, California, United States | — |
| Center for Dermatology Clinical Research, Inc. | Fremont, California, United States | — |
| California Allergy and Asthma Medical Group | Los Angeles, California, United States | — |
| University of California Los Angeles Dermatology | Los Angeles, California, United States | — |
| Amicis Research Center (Northridge) | Northridge, California, United States | — |
| Cura Clinical Research | Oxnard, California, United States | — |
| VASDHS - Veterans Affairs San Diego Medical Center | San Diego, California, United States | — |
| Clinical Sciences Institute | Santa Monica, California, United States | — |
| Renaissance Research and Medical Group | Cape Coral, Florida, United States | — |
| D&H National Research Centers, Inc. | Miami, Florida, United States | — |
+ 23 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06436183